Scholars Central

Editor

Srinivasan Shanmugam

Project Leader, Hanmi Pharm. Co. Ltd, South Korea

About

As published by the journal they serve.

Dr. Srinivasan Shanmugam received his Ph.D. in Pharmaceutical Science from the College of Pharmacy, Yeungnam University in 2010. During his doctoral studies, his research was on liposomes, niosomes, and chemical enhancers for topical delivery and self-emulsifying drug delivery systems (SNEDDS) for oral delivery. He received his MS in Pharmaceutical Sciences in the same university in the year of 2007, and his research focus during this period was on mixed micellar nanoparticles for parenteral and liposomes for topical delivery. His undergraduate major was Pharmacy (Bachelor of Phramacy) and received his degree in the year of 1999 with research focus on “Endothelin Receptors.” Right after undergraduate degree, he gained hands on experience in manufacturing of solid/liquid dosage formulations by working in pharmaceutical companies for about five years. Currently, Dr. Shanmugam is a Project Leader (Principal Scientist) in Formulation R&D Division of Hanmi Pharm. Co. Ltd., South Korea. His research focuses on design and development of conventional, NDDS/alternate/advanced, and modified drug delivery systems, and platform technologies. He has successfully designed, developed, and implemented various platform technologies to enhance oral bioavailability of highly hydrophilic drugs, poorly bioavailable highly lipophilic drugs, etc. Dr. Shanmugam has published numerous research articles in prestigious pharmaceutical sciences journals and presented more than 20 of his work in various symposiums/conferences globally. He is also a reviewer and editorial member of various journals.

Research interests

  • Yeungnam University in 2010. During his doctoral studies
  • his research was on liposomes
  • niosomes
  • South Korea. His research focuses on design and development of conventional
  • NDDS/alternate/advanced
  • and modified drug delivery systems
  • and platform technologies. He has successfully designed
  • developed
  • poorly bioavailable highly lipophilic drugs

Journals they serve

The seats these journals name them in.

Articles we hold

Articles in the journals they serve whose byline carries this name.

This page holds what the journals publish about this profile: no contact details, and nothing gathered from anywhere else. Ask us to correct or remove this profile.

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels